医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

athenahealth and Smile Foundation Launch Second Mobile Medical Unit in Bengaluru

2023年04月04日 PM11:00
このエントリーをはてなブックマークに追加


 

WATERTOWN, Mass.

athenahealth, Inc., a leading provider of network-enabled software and services for medical groups and health systems nationwide, and Smile Foundation today announced the expansion of their partnership with the launch of a second mobile medical unit, as part of the Smile on Wheels initiative, in Bengaluru, India. The mobile medical unit provides free care to underprivileged and underserved communities in Karnataka state.

The expansion is a result of the success of the partnership’s first mobile medical unit, which was launched in August 2021 to help strengthen public health infrastructure and provide primary healthcare to Chennai residents. To date, the original unit has served more than 25,000 people. athenaGives, athenahealth’s corporate social responsibility (CSR) program, provides financial support for the Smile on Wheels mobile medical units.

In addition to healthcare accessibility, another objective of the second mobile medical unit in Bengaluru is safe motherhood, ensuring all women receive the care they need to be healthy throughout pregnancy and childbirth and to reduce the number of maternal mortalities.

Smile on Wheels is a national-level mobile healthcare program from Smile Foundation that benefits underprivileged communities. Through the program, well-equipped mobile medical units, along with specialized doctors, nurses, and medical staff, reach out to villages in underserved urban communities to provide crucial access to primary healthcare services. Smile on Wheels has to date provided free healthcare services to more than 1.5 million children and families across India.

“Ensuring the proper healthcare for children and young mothers is crucial for the people of Karnataka. We are glad to take our partnership with athenahealth further and to complement the healthcare efforts of the government,” said Mr. Santanu Mishra, co-founder and executive trustee at Smile Foundation.

“We are proud to partner with Smile Foundation to support patients in underprivileged communities in India,” said Gillian Perron, head of athenaGives at athenahealth. “Maternal health is a global issue, and we look forward to continuing to work with organizations both in India and the United States to help improve pregnancy and childbirth outcomes.”

Learn more about athenaGives and athenaGives India.

About athenahealth, Inc.

athenahealth creates innovative healthcare technology that connects clinicians, patients, payers, and partners in differentiated ways. Our electronic health record, revenue cycle management, and patient engagement tools allow anytime, anywhere access, driving better financial outcomes for our customers and enabling our provider customers to deliver better quality care. In everything we do, we’re inspired by our vision to create a thriving ecosystem that delivers accessible, high-quality, and sustainable healthcare for all. For more information, please visit www.athenahealth.com.

athenaGives is athenahealth’s global corporate social responsibility program with a mission to provide equitable access to healthcare for all; improve food security; and support science, technology, engineering, and math (STEM) education.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230403005596/en/

CONTACT

Nikki D’Addario   

ndaddario@athenahealth.com  

(617) 393-6004  

同じカテゴリーの記事 

  • Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
  • Huonslab Announces Positive Results from In Vivo comparative PK study of Trastuzumab/HyDIFFUZETM compared with marketed rHuPH20 co-formulation with Trastuzumab
  • Rapid Medical™、TIGERTRIEVER™13を用いたDISTALS臨床試験の中間安全性解析で、中血管閉塞の安全性の懸念がないことを報告
  • Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration
  • JCR Pharmaceuticals’ Data Presentations at SSIEM Annual Symposium 2024 Highlight Investigational Treatments for Lysosomal Storage Disorders